High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis

Παρόμοια τεκμήρια

• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  ανά: Messori, Andrea, κ.ά.
  Έκδοση: (2019)
• Reply to “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis” by Messori et al.
  ανά: Farrugia, Albert, κ.ά.
  Έκδοση: (2019)
• Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
  ανά: Mannucci, Pier Mannuccio
  Έκδοση: (2010)
• Factor VIII inhibitor and source of replacement therapy
  ανά: Mannucci, Pier Mannuccio, κ.ά.
  Έκδοση: (2012)
• Factor VIII replacement is still the standard of care in haemophilia A
  ανά: Aledort, Louis, κ.ά.
  Έκδοση: (2019)